Login / Signup

Interpretation of low reactivity in the Abbott Architect rHTLV I/II assay.

J H C TosswillGraham P Taylor
Published in: Transfusion medicine (Oxford, England) (2017)
Samples with an S/CO ratio of <4·0 on the Abbott Architect rHTLV I/II platform represent a low risk of HTLV infection in the UK, and organs from such donors might reasonably be considered for transplantation, within the context of appropriate risk-benefit assessment.
Keyphrases
  • high throughput
  • cross sectional
  • cell therapy